We hypothesised that trastuzumab therapy for women with HER2+ breast cancer may not be cost-effective for older patients, nor for the better prognosis subtypes (ER+/PR+, ER+/PR−, and ER−/PR+), and doubly so for older women with better prognosis subtypes. Here, PGR is linked to breast carcinoma.